RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      Catheter-Related Trichosporon asahii Bloodstream Infection in a Neutropenic Patient with Myelodysplastic Syndrome

      한글로보기

      https://www.riss.kr/link?id=A106071006

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Because primary antifungal prophylaxis is widely used for immunocompromised hosts, the incidences of unusual fungal infections have increased. Trichosporon asahii has emerged as an important life-threatening opportunistic systemic pathogen because of ...

      Because primary antifungal prophylaxis is widely used for immunocompromised hosts, the incidences of unusual fungal infections have increased. Trichosporon asahii has emerged as an important life-threatening opportunistic systemic pathogen because of the increased use of cytotoxic or immunosuppressant agents, along with high mortality rates. Here, we describe a case of catheter-related T. asahii bloodstream infection with multiple septic skin nodules in both the arms and legs of the patient who was in the neutropenic period after allogeneic stem cell transplantation for myelodysplastic syndrome treated with prophylactic ciprofloxacin and itraconazole. We successfully treated her with intravenous voriconazole for more than a month without any complications. Clinicians should consider breakthrough Trichosporon infections when clinical progress in an immunocompromised patient with unexplained infection signs and symptoms does not improve despite proper treatment with antibiotics or various antifungal agents. In addition, voriconazole can be a good treatment choice for achieving better treatment results and prognosis.

      더보기

      참고문헌 (Reference)

      1 장문주, "급성골수성백혈병 환자에서Amphotericin B와 Fluconazole로 치료된 Trichosporon beigelii진균혈증 1례" 대한혈액학회 39 (39): 109-112, 2004

      2 Chen J, "Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazole" 6 : 55-57, 2014

      3 Kim YJ, "Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient" 37 : 366-369, 2007

      4 Asada N, "Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia" 43 : e39-e41, 2006

      5 Dua V, "Successful treatment of Trichosporon asahii infection with voriconazole after bone marrow transplant" 35 : 237-238, 2013

      6 Liao Y, "Serum glucuronoxylomannan may be more appropriate for the diagnosis and therapeutic monitoring of Trichosporon fungemia than serum -D-glucan" 16 : e638-, 2012

      7 Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeast; 4th informational supplement"

      8 Nachbaur D, "Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study" 94 : 258-264, 2015

      9 Menezes EA, "Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceara, Brazil" 54 : 1-3, 2012

      10 Ruan SY, "Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan" 49 : e11-e17, 2009

      1 장문주, "급성골수성백혈병 환자에서Amphotericin B와 Fluconazole로 치료된 Trichosporon beigelii진균혈증 1례" 대한혈액학회 39 (39): 109-112, 2004

      2 Chen J, "Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazole" 6 : 55-57, 2014

      3 Kim YJ, "Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient" 37 : 366-369, 2007

      4 Asada N, "Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia" 43 : e39-e41, 2006

      5 Dua V, "Successful treatment of Trichosporon asahii infection with voriconazole after bone marrow transplant" 35 : 237-238, 2013

      6 Liao Y, "Serum glucuronoxylomannan may be more appropriate for the diagnosis and therapeutic monitoring of Trichosporon fungemia than serum -D-glucan" 16 : e638-, 2012

      7 Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeast; 4th informational supplement"

      8 Nachbaur D, "Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study" 94 : 258-264, 2015

      9 Menezes EA, "Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceara, Brazil" 54 : 1-3, 2012

      10 Ruan SY, "Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan" 49 : e11-e17, 2009

      11 Auberger J, "Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in highrisk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study" 67 : 2268-2273, 2012

      12 Suzuki K, "Fatal Trichosporon fungemia in patients with hematologic malignancies" 84 : 441-447, 2010

      13 강승훈, "Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis" 대한감염학회 47 (47): 49-54, 2015

      14 Arendrup MC, "ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections" 20 (20): 76-98, 2014

      15 Colombo AL, "Current knowledge of Trichosporon spp. and Trichosporonosis" 24 : 682-700, 2011

      16 Malani AN, "Changing epidemiology of rare mould infections: implications for therapy" 67 : 1803-1812, 2007

      17 Matsue K, "Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin" 42 : 753-757, 2006

      18 Rieger C, "Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia" 26 : 843-845, 2007

      19 Bayramoglu G, "Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin" 36 : 68-70, 2008

      20 Shimono J, "Acute renal tubular damage caused by disseminated Trichosporon infection in primary myelofibrosis" 56 : 21-24, 2015

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2010-02-25 학술지명변경 한글명 : 감염과화학요법 -> Infection and Chemotherapy
      외국어명 : Infection and Chemotherapy -> 미등록
      KCI등재후보
      2010-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2009-08-25 학술지명변경 외국어명 : 미등록 -> Infection and Chemotherapy KCI등재후보
      2008-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      2008-01-01 평가 등재후보 탈락 (등재후보1차)
      2006-01-01 평가 등재후보 1차 FAIL (등재후보2차) KCI등재후보
      2005-05-27 학술지등록 한글명 : 감염과화학요법
      외국어명 : 미등록
      KCI등재후보
      2005-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2004-01-01 평가 등재후보 1차 FAIL (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.24 0.24 0.24
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.2 0.2 0.46 0.29
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼